IRCT20171030037093N37招募中3 期
Evaluation of the nephroprotective effect of lycopene in patients receiving vancomycin
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Serum creatinine levels less than 1.2 mg / dl at the start of the study
- •Creatinine clearance (ClCr)> 90 ml / min upon admission
- •Lack of underlying renal impairment such as glomerulonephritis, polycystic kidney disease, kidney stones, interstitial nephritis, renal artery stenosis and renal carcinoma
- •Lack of underlying diseases causes kidney disorders such as diabetes mellitus and high blood pressure
- •Hospital history and failure to receive other nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, tacrolimus and furosemide, etc.
- •Do not take other antioxidant supplements such as vitamins C and E.
排除标准
- •History of acute kidney damage
- •Lycopene allergy history
- •History of injectable addiction
研究者
相似试验
已完成
不适用
The investigation of the renal protective effect of Carperitide(hANP:human atrial natriuretic peptide) during adult living donor renal transplantation, a single center experience.living donor renal transplantationJPRN-UMIN000014279Toho University School of Medicine, Department of Anesthesiology30
尚未招募
不适用
Study of renal function renal protective effect of cooling method in laparoscopic partial nephrectomyRenal cell cacinomaJPRN-UMIN000013867Kansai Medical University30
招募中
3 期
Evaluation of nephroprotective effects of Melatoniung? head and neck? genitourinary system or gastrointestinal cancers.C07 Malignant neoplasm of parotid gland , C08 Malignant neoplasm of other and unspecified major salivary glands, C09 Malignant neoplasm of tonsil , C10 Malignant neoplasm of oropharynx, C11 Malignant neoplasm of nasopharynx, C12 Malignant neoplasmC7, C8 ,IRCT20171225038073N1Tehran University of Medical Sciences50
进行中（未招募）
1 期
This study will assess the effects of dapagliflozin (a drug that is used in patients with Type 2 Diabetes) on lowering the level of urine protein in patients with non-diabetic kidney disease.Chronic kidney diseaseEUCTR2017-001090-16-NLniversity Medical Center Groningen53
已完成
不适用
The protective effect for renal function of Aliskiren in hypertensive CKD patients with proteinuriahypertensive patients with chronic kidney diseaseJPRN-UMIN000005759Department of Internal Medicine, Division of Nephrology, Juntendo University Faculty of Medicine153